| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Intellipharmaceutics International Inc (OTCQB: IPCIF)
IPCIF Technical Analysis
5
| As on 9th Jun 2023 IPCIF STOCK Price closed @ 0.06 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.11 & Strong Sell for SHORT-TERM with Stoploss of 0.13 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IPCIFSTOCK Price
| Open | 0.04 | Change | Price | % |
| High | 0.06 | 1 Day | 0.03 | 100.00 |
| Low | 0.03 | 1 Week | 0.01 | 20.00 |
| Close | 0.06 | 1 Month | 0.01 | 20.00 |
| Volume | 22447 | 1 Year | -0.04 | -40.00 |
| 52 Week High 0.20 | 52 Week Low 0.01 | ||||
OTCQB USA Most Active Stocks
| BMIX | 0.01 | % |
| MOBQ | 0.18 | -5.26% |
| FNMA | 0.45 | 0.00% |
| ALPP | 3.56 | -0.80% |
| ALPP | 3.56 | -0.80% |
| SHMP | 0.06 | 0.00% |
| NWBO | 0.73 | 0.00% |
| VPLM | 0.08 | % |
| NLST | 3.72 | -8.60% |
| SRNA | 2.78 | 14.88% |
OTCQB USA Top Gainers Stocks
OTCQB USA Top Losers Stocks
| IPCIF Daily Charts |
IPCIF Intraday Charts |
Whats New @ Bazaartrend |
IPCIF Free Analysis |
|
|
IPCIF Important Levels Intraday
| RESISTANCE | 0.12 |
| RESISTANCE | 0.10 |
| RESISTANCE | 0.09 |
| RESISTANCE | 0.08 |
| SUPPORT | 0.04 |
| SUPPORT | 0.03 |
| SUPPORT | 0.02 |
| SUPPORT | 0.00 |
IPCIF Forecast April 2024
| 4th UP Forecast | 0.43 |
| 3rd UP Forecast | 0.31 |
| 2nd UP Forecast | 0.24 |
| 1st UP Forecast | 0.16 |
| 1st DOWN Forecast | -0.04 |
| 2nd DOWN Forecast | -0.12 |
| 3rd DOWN Forecast | -0.19 |
| 4th DOWN Forecast | -0.31 |
IPCIF Weekly Forecast
| 4th UP Forecast | 0.14 |
| 3rd UP Forecast | 0.11 |
| 2nd UP Forecast | 0.10 |
| 1st UP Forecast | 0.08 |
| 1st DOWN Forecast | 0.04 |
| 2nd DOWN Forecast | 0.02 |
| 3rd DOWN Forecast | 0.01 |
| 4th DOWN Forecast | -0.02 |
IPCIF Forecast2024
| 4th UP Forecast | 0.62 |
| 3rd UP Forecast | 0.44 |
| 2nd UP Forecast | 0.33 |
| 1st UP Forecast | 0.22 |
| 1st DOWN Forecast | -0.1 |
| 2nd DOWN Forecast | -0.21 |
| 3rd DOWN Forecast | -0.32 |
| 4th DOWN Forecast | -0.5 |
Intellipharmaceutics International Inc ( OTCQB USA Symbol : IPCIF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IPCIF Business Profile
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin XR and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada. Address: 30 Worcester Road, Toronto, ON, Canada, M9W 5X2
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service